Business
Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblasto...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Sept 25, 2019\n\n\n\n-Patients treated at the high dose show impressive survival benefit--IL4R population surviving twice as long as current approved treatments-\n TORONTO and HOUSTON, Sept 25, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company developing first-in-class Superkines and Empowered Cytokines, today presented updated clinical results from its Phase 2b clinical trial of MDNA55, an IL4-guided toxin, in patients with recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at the Inaugural Targeting Innate Immunity Congress held from September 23-25, 2019 in Cambridge, MA.\nThe presentation by Dr. Fahar Merchant, President & CEO of Medicenna, focused on updated efficacy results from the Phase 2b clinical trial MDNA55-05 in rGBM patients using the interleukin 4 receptor (IL4R) as an immunotherapy target, as it is overexpressed in glioblastoma as well as in cells that make up the brain tumor microenvironment (TME). \n\"The data continues to show very promising results for MDNA55 when compared to approved therapies for rGBM. These new findings are consistent with previous results showing that patients suffering from rGBM, particularly those with the IL4R biomarker an indicator of a more aggressive form of rGBM, are surviving substantially longer with just one treatment,\" states Dr. Fahar Merchant. \"This is very exciting for both Medicenna and the broader health community, as this not only offers considerable benefit to patients with this devastating disease, but also offers hope for patients with at least 20 other cancer indications where the tumor and associated tumor microenvironment over-expresses the IL4R.\"\nThese data imply that targeting the TME, particu...